Abemaciclib

Major

Abemaciclib Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Abemaciclib Lenacapavir Sunlenca Explained Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Abemaciclib Lonafarnib Zokinvy Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Abemaciclib Lumacaftor Explained Decreased abemaciclib plasma concentration Details Abemaciclib Mavorixafor Xolremdi Explained Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Abemaciclib Metformin Fortamet® Increased metFORMIN exposure and an increased risk of lactic acidosis Details Abemaciclib Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Abemaciclib Mitotane Lysodren Explained Decreased abemaciclib plasma concentration Details Abemaciclib Mobocertinib Exkivity Explained Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Abemaciclib Nirmatrelvir Explained Increased abemaciclib plasma concentration Details Abemaciclib Nirogacestat Ogsiveo Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Abemaciclib Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Abemaciclib Omaveloxolone Skyclarys Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Abemaciclib Pacritinib Vonjo® Explained Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Abemaciclib Palbociclib Ibrance Explained Increased exposure to CYP3A substrates with a narrow therapeutic index Details Abemaciclib Phenobarbital Fidoquel Explained Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Abemaciclib Phenytoin Dilantin Explained Decreased abemaciclib plasma concentration Details Abemaciclib Pimozide Explained Increased pimozide exposure and an increased risk of pimozide-related adverse reactions Details Abemaciclib Primidone Mysoline Explained Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Abemaciclib Ranolazine Aspruzyo Explained Increased exposure of CYP3A4 substrate Details Abemaciclib Relacorilant Lifyorli Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Abemaciclib Repotrectinib Augtyro Explained Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Abemaciclib Ribociclib Kisqali Explained Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Abemaciclib Rifampin Rifadin Explained Decreased abemaciclib plasma concentration Details Abemaciclib Ritlecitinib Litfulo Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Abemaciclib Rotavirus Vaccine, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Selpercatinib Retevmo Explained Increased substrate exposure and an increased risk for adverse effects Details Abemaciclib Sevabertinib Hyrnuo Explained Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Abemaciclib Sotorasib Lumakras Explained Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Abemaciclib St John's Wort Explained Decreased abemaciclib plasma concentration Details Abemaciclib Suzetrigine Journavx Explained Reduced sensitive CYP3A substrate with NTI exposure and reduced efficacy of sensitive CYP3A substrate with NTI Details Abemaciclib Taurursodiol Explained Decreased exposure of the CYP3A4 substrate Details Abemaciclib Tazemetostat Tazverik Explained Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Abemaciclib Tizanidine Explained Increased tiZANidine exposure and an increased risk of tiZANidine-related hypotension, bradycardia or increased drowsiness Details Abemaciclib Tocilizumab Actemra Explained Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Abemaciclib Tovorafenib Ojemda Explained Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Abemaciclib Treosulfan Grafapex Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse and serious life-threatening toxicit... Details Abemaciclib Trofinetide Daybue Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Abemaciclib Tucatinib Tukysa Explained Increased exposure to CYP3A substrate and risk of toxicity Details Abemaciclib Vonoprazan Voquezna Explained Increased CYP3A substrates exposure Details